
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is poised for long-term success, with a strong leadership team in place and a solid portfolio of phakic intraocular lenses that are in high demand, specifically in China. This is evident from their current financial results, with a significant increase in revenue and a positive outlook for future growth in the country. Their competitive moat, reinforced by their proprietary Collamer material and established track record, is further enhanced by their focus on surgeon training and clinic workflows. With a potential market share ramp for competitors such as EyeBright, monitoring their progress will be important, but we believe that Staar Surgical's strong brand equity and technological lead will allow them to maintain their dominant market position.
Bears say
Staar Surgical is heavily reliant on its ICL products, which may hinder long-term growth as the market for intraocular procedures is largely dominated by laser-based alternatives. Moreover, the company's narrow focus on the refractive surgery market leaves it vulnerable to competition and shifts in consumer preference. Lastly, strong support for ICL adoption among younger and newer surgeons is not a guarantee for sustained sales growth as these surgeons may choose to prioritize other procedures or shift to alternative techniques in the future.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares